Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine for COVID-19 ARDS
NCT04979884Phase 3Completed
- Sponsor
- Alexandria University
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) comparing Cyclosporine + SOC with Standard of Care (2 arms). Primary endpoint: Percentage of subjects with a 6-point ordinal scale showing each severity level. Started Jan 2022; status: completed.
02
Drugs
cyclosporine
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04979884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979884.